GJA1 and glaucoma: These studies suggest that targeting the regulation of Cx43 is emerging as a promising therapeutic strategy for glaucoma, particularly in its later stages, where mitigating ATP release from macroglial cells and the associated dissemination of pro‐inflammatory mediators could offer significant neuroprotection.